-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Mitiperstat
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Mitiperstat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: BioNTech SE’s Gotistobart
Empower your strategies with our Net Present Value Model: BioNTech SE's Gotistobart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-321 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-321 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-321 in Solid Tumor Drug Details: MVT-5873 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DB-1311 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1311 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DB-1311 in Solid Tumor Drug Details: DB-1311 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-151 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Non-Small Cell Lung Cancer Drug Details: BNT-151...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-151 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Head And Neck Squamous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DB-1311 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1311 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DB-1311 in Non-Small Cell Lung Cancer Drug Details: DB-1311 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-151 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Triple-Negative Breast Cancer (TNBC) Drug Details: BNT-151...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-151 in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Hepatocellular Carcinoma Drug Details: BNT-151 is under development for...